Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center Translational...

Poniard Pharmaceuticals to Present at the 4th Annual Moores UCSD Cancer Center
Translational Oncology Symposium

SOUTH SAN FRANCISCO, Calif., July 31 /PRNewswire-FirstCall/ -- Poniard
Pharmaceuticals, Inc. (Nasdaq: PARD), a biopharmaceutical company focused on
oncology, today announced that the Company will present information on
platinum resistance at the Fourth Annual Moores UCSD Cancer Center
Translational Oncology Symposium on Friday, August 1, in San Diego.
Neela Patel, Ph.D., director of preclinical and translational medicine for
Poniard Pharmaceuticals, will present on the topic of "Molecular Mechanisms of
Platinum Resistance" at 2:30 p.m. Pacific Time. Jerry McMahon, Ph.D., chairman
and chief executive officer, will participate in the symposia's concluding
panel discussion at 3:15 p.m. Pacific Time.
"Each year, 300,000 cancer patients in the United States are treated with
a platinum-based chemotherapy, and most relapse after initial treatment," said
Dr. McMahon. "Therefore, intrinsic or acquired resistance to platinums is a
significant treatment issue. Picoplatin, our lead product candidate, was
designed to overcome platinum resistance, and we are exploring the use of
genetic markers of platinum resistance to optimize patient treatment."
About The Rebecca and John Moores UCSD Cancer Center
The Rebecca and John Moores UCSD Cancer Center seeks to bring the finest
minds in treatment and research under one roof to share the latest advances in
the oncology field, and to create a fertile atmosphere that promotes
networking and collaboration opportunities of benefit to all participants.
Information about the Moores UCSD Cancer Center and the Translational
Oncology Symposium can be found at http://cancer.ucsd.edu/symposium/index.asp.
About Poniard Pharmaceuticals
Poniard Pharmaceuticals, Inc. is a biopharmaceutical company focused on
the development and commercialization of innovative oncology products to
impact the lives of people with cancer. Picoplatin, the Company's lead
platform product candidate, is a new generation platinum therapy with an
improved safety profile relative to existing platinum-based cancer therapies.
Picoplatin is designed to overcome platinum resistance associated with
chemotherapy in solid tumors, and is being studied in multiple cancer
indications, combinations and formulations. Clinical trials of intravenous
picoplatin include a Phase 3 trial in small cell lung cancer and Phase 2
trials in metastatic colorectal and hormone-refractory prostate cancers, as
well as a clinical trial of oral picoplatin in solid tumors. Picoplatin has
not been approved by any regulatory authority for use in humans. For
additional information please visit http://www.poniard.com.
(C) 2008 Poniard Pharmaceuticals, Inc. All Rights Reserved.
Poniard and Poniard Pharmaceuticals are trademarks of Poniard
Pharmaceuticals, Inc.
SOURCE Poniard Pharmaceuticals

Brendan Doherty, Corporate Communications of Poniard Pharmaceuticals,
+1-650-745-4425, bdoherty@poniard.com